OncoTherapy Science, Inc. (TYO:4564)
Japan
· Delayed Price · Currency is JPY 23.00
-1.00 (-4.17%)
May 2, 2025, 3:30 PM JST
OncoTherapy Science Revenue
OncoTherapy Science had revenue of 338.00M JPY in the quarter ending December 31, 2024, with 207.27% growth. This brings the company's revenue in the last twelve months to 707.00M, down -21.53% year-over-year. In the fiscal year ending March 31, 2024, OncoTherapy Science had annual revenue of 610.00M, down -46.21%.
Revenue (ttm)
707.00M
Revenue Growth
-21.53%
P/S Ratio
8.97
Revenue / Employee
13.09M
Employees
54
Market Cap
6.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 610.00M | -524.00M | -46.21% |
| Mar 31, 2023 | 1.13B | -19.00M | -1.65% |
| Mar 31, 2022 | 1.15B | 821.00M | 247.29% |
| Mar 31, 2021 | 332.00M | 16.00M | 5.06% |
| Mar 31, 2020 | 316.00M | 36.00M | 12.86% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,222.12B |
| Daiichi Sankyo Company | 1,886.26B |
| Takeda Pharmaceutical Company | 4,579.02B |
| HOYA Corporation | 838.60B |
| Terumo | 1,011.15B |
| Otsuka Holdings | 2,329.86B |
| Astellas Pharma | 1,912.32B |
| Olympus | 993.33B |